PXE

Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency

Retrieved on: 
Monday, April 8, 2024
Patient, Cerebrovascular disease, Stroke, Accelerated approval (FDA), European Medicines Agency, Doctor of Philosophy, Osteomalacia, PROMIS, Therapy, Conditional, Natural history, CTX, Pros, ADAS, Risk, DSM-IV codes, Cohort, Aes, Alkaline phosphatase, Rickets, EMA, PXE, Safety, Epilepsy, Clinical trial, Food, Hospital, Disability, BSAP, Cardiovascular disease, Disease, PD, Paresis, Consultant, Hypophosphatemia, Fatigue, Survivor, Sclera, FDA, Observational study, Pyrophosphate, Choroid, Incidence, Retina, Biomarker, Life, Event, Medical imaging

BOSTON, April 08, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced positive topline safety, pharmacokinetic (PK), pharmacodynamic (PD) and exploratory efficacy data from the Company’s ongoing Phase 1/2 clinical trials of INZ-701 in adults with ABCC6 Deficiency (PXE, pseudoxanthoma elasticum) and ENPP1 Deficiency.

Key Points: 
  • “We are excited by the excellent safety and preliminary efficacy profile of INZ-701 in adults with ABCC6 Deficiency,” said Douglas A. Treco, Ph.D., CEO of Inozyme Pharma.
  • The patients were assigned to three dose cohorts of INZ-701: 0.2 mg/kg (n=3), 0.6 mg/kg (n=3), and 1.8 mg/kg (n=4).
  • For trial design details, please see the section entitled “INZ-701 in ABCC6 Deficiency Phase 1/2 Clinical Trial Design” below.
  • For trial design details, please see the section entitled “INZ-701 in ENPP1 Deficiency Phase 1/2 Clinical Trial Design” below.

Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024

Retrieved on: 
Tuesday, March 26, 2024
Neurology, Hospital, Consultant, Webcast, Patient, PXE, Event, Therapy, Pharmaceutical industry

BOSTON, March 26, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that it will host a conference call and webcast on Monday, April 8, 2024 at 8:00 a.m. Eastern Time.

Key Points: 
  • - Company to host conference call and webcast featuring key opinion leaders on Monday, April 8, 2024 at 8:00 a.m.
  • During the conference call and webcast, the Company will discuss topline data from its ongoing Phase 1/2 trial of INZ-701 in adults with ABCC6 Deficiency (pseudoxanthoma elasticum or PXE), and from all cohorts of its ongoing Phase 1/2 trial of INZ-701 in adults with ENPP1 Deficiency.
  • Alternatively, the conference call may be accessed by dialing:
    Participants should ask to join the Inozyme Pharma call.
  • For those unable to participate live, a replay will be available in the Investor Relations section of Inozyme’s website for a limited time following the event.

Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights

Retrieved on: 
Tuesday, March 12, 2024
Administration, Plasma, Kidney disease, ECTS, Massachusetts General Hospital, Pyrophosphate, PD, ASN, Partnership, Pharmacokinetics, Calciphylaxis, G&A, PROPEL, Doctor of Philosophy, Chemistry, Investment, PXE, Society, Pathology, Therapy, Safety, Research and development, ESKD, ENPP1, MMSc, Natural history, Pharmaceutical industry

BOSTON, March 12, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today reported financial results for the full year ended December 31, 2023, and provided recent business highlights.

Key Points: 
  • “We believe we are well-positioned to continue to advance INZ-701 through several anticipated value-creating milestones in the year ahead,” said Douglas A. Treco, Ph.D., CEO of Inozyme Pharma.
  • Calciphylaxis represents a devastating condition characterized by pathologic mineralization and intimal proliferation.
  • Patients will receive 1.8 mg/kg of INZ-701 once weekly, coinciding with their hemodialysis treatment, for a total of 30 days.
  • The study’s primary endpoint will assess safety and change from baseline plasma PPi concentration, with secondary endpoints including PK and PD parameters.

Alleviate Administrative Challenges with Noridian’s Payer Product Suite

Retrieved on: 
Wednesday, March 6, 2024
Software, Managed Care, Professional Services, Data Management, Payments, Technology, Health Technology, Health Insurance, Data Analytics, Insurance, Practice Management, Health, Multimedia, EDI, CMS, Education, Credentialing, Utilization, Medicare, PXE, Medicaid, Financial management, Partnership, Health insurance

Noridian Payer Experience Elevated (PXe) is intentionally designed to elevate payers’ health plan operations by eliminating administrative barriers.

Key Points: 
  • Noridian Payer Experience Elevated (PXe) is intentionally designed to elevate payers’ health plan operations by eliminating administrative barriers.
  • Noridian PXe represents the company’s commitment to continue expanding its offerings to new health plans nationwide.
  • “Noridian PXe is focused on operational areas that cause common administrative problems for health plans.
  • The product suite of payer services includes:
    Noridian PXe Provider Management: Noridian processes nearly 260,000 provider enrollment applications annually and works with over 400,000 providers to perform credentialing and enrollment, site visits and outreach & education services.

Inozyme Pharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights

Retrieved on: 
Tuesday, November 7, 2023
Generalized arterial calcification of infancy, Patient, Research, Research and development, Genomics, Clinical trial, PD, Calciphylaxis, Therapy, Biomarker, ESKD, G&A, American Society of Nephrology, Conference, Pros, Kidney disease, R, American Society for Bone and Mineral Research, Society, PXE, Columbia University School of General Studies, ENPP1, ASN, PK, Clinical Global Impression, Annual general meeting, GIC, Safety, ABCC6, Investment, Doctor of Philosophy, Administration, Nursing, Pharmaceutical industry

BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today reported financial results for the third quarter ended September 30, 2023 and provided business highlights.

Key Points: 
  • Patient recruitment is underway, and the Company remains on track to report topline data in mid-2025.
  • Exploratory efficacy data reported suggested clinical benefit for ENPP1 Deficiency, including improvement in key biomarkers, patient-reported outcomes (PROs), and functional outcomes.
  • R&D Expenses were $13.3 million for the quarter ended September 30, 2023, compared to $12.2 million for the prior-year period.
  • Net loss was $16.6 million, or $0.29 loss per share, for the quarter ended September 30, 2023, compared to $16.4 million, or $0.38 loss per share, for the prior-year period.

Inozyme Pharma Announces Three Poster Presentations at the American Society for Bone and Mineral Research (ASBMR) 2023 Annual Meeting

Retrieved on: 
Friday, October 6, 2023
Annual general meeting, Senior, Therapy, Society, American Society for Bone and Mineral Research, Interim analysis, PXE, Associate professor, University of Connecticut, Dentistry, University of Connecticut Health Center, Pseudoxanthoma elasticum, Pharmaceutical industry, Management, Pharmacokinetics, Safety

BOSTON, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that it will present three posters at the American Society for Bone and Mineral Research (ASBMR) 2023 Annual Meeting, which is being held October 13-16, 2023 in Vancouver, BC, Canada.

Key Points: 
  • BOSTON, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that it will present three posters at the American Society for Bone and Mineral Research (ASBMR) 2023 Annual Meeting, which is being held October 13-16, 2023 in Vancouver, BC, Canada.
  • Details of the presentations are as follows:
    Title: A Phase 1/2 Open-Label, Multiple Ascending Dose Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INZ-701 in Adults with ENPP1 Deficiency
    Author/Presenter: Yves Sabbagh, Ph.D. (Senior Vice President and Chief Scientific Officer, Inozyme Pharma)
    Title: A Phase 1/2 Open-Label, Multiple Ascending Dose Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INZ-701 Followed by an Open-Label Long-Term Extension Period in Adults with ABCC6 Deficiency Manifesting as Pseudoxanthoma Elasticum (PXE): An Interim Analysis
    Author/Presenter: Yves Sabbagh, Ph.D. (Senior Vice President and Chief Scientific Officer, Inozyme Pharma)
    Author/Presenter: I-Ping Chen, D.D.S., Ph.D. (Associate Professor, Oral Health and Diagnostic Sciences, UConn Health)

Inozyme Pharma Announces Positive Interim Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE)

Retrieved on: 
Tuesday, September 26, 2023
PROMIS, BMC, Pros, Pediatric emergency medicine, Pediatrics, PD, Therapy, Hypophosphatemia, BSAP, Fatigue, Medicine, Phase II, New Çeltek events, Biomarker, BMD, Appetite, Hives, Pyrophosphate, Parallel Walk Test, Rapids, Alkaline phosphatase, Pain, Bruise, ET, Clinical trial, Bleeding, ADAS, Patient, Physician, PXE, Swelling, Itch, Erythema, Division, Adolescence, Osteomalacia, Infant, DEXA, Rickets, GIC, ADA, Diabetes, Titanium metallic discoloration, Safety, Dietary supplement, Pharmaceutical industry, Nursing, Medical imaging, Phosphorus, Birth control, Risk management, Vaccine, Endocrinology, News

BOSTON, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced positive interim safety, pharmacokinetic (PK), pharmacodynamic (PD) and exploratory efficacy data from the Company’s ongoing Phase 1/2 clinical trials of INZ-701 in adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE, pseudoxanthoma elasticum).

Key Points: 
  • For trial design details, please see the section entitled “INZ-701 in ENPP1 Deficiency Phase 1/2 Clinical Trial Design” below.
  • Exploratory biomarker data were collected throughout the study to provide evidence of the potential for disease modification with ongoing treatment with INZ-701.
  • For trial design details, please see the section entitled “INZ-701 in ABCC6 Deficiency Phase 1/2 Clinical Trial Design” below.
  • PK properties were consistent with those observed in the Phase 1/2 clinical trial in adults with ENPP1 Deficiency.

Inozyme Pharma to Host Virtual Investor and Analyst Event on Sep. 26, 2023

Retrieved on: 
Wednesday, September 20, 2023
Webcast, Therapy, Patient, PXE, Safety, Pharmaceutical industry

BOSTON, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY)(“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that it will host an Investor and Analyst Event on Tuesday, September 26, 2023 at 8:00 a.m. Eastern Time.

Key Points: 
  • BOSTON, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY)(“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that it will host an Investor and Analyst Event on Tuesday, September 26, 2023 at 8:00 a.m. Eastern Time.
  • The live webcast will be accessible through the Investor Relations section of Inozyme’s website under events .
  • Alternatively, the conference call may be accessed by dialing:
    Participants should ask to join the Inozyme Pharma call.
  • For those unable to participate live, a replay will be available in the Investor Relations section of Inozyme’s website for a limited time following the event.

EQS-News: Superstar Gaming Marketer Adam Ivers joins P2Earn Advisory Board

Retrieved on: 
Saturday, May 27, 2023
Organization, Knowledge, CSE, Social media, FSE, PXE, Marketing, Rumble, Advisory board, Video game

Toronto, Canada - (May 23, 2023) - P2Earn Inc (CSE:PXE) (FSE:WH4) is pleased to announce the addition of Adam Ivers, CEO of Rumble Gaming, to its Advisory Board.

Key Points: 
  • Toronto, Canada - (May 23, 2023) - P2Earn Inc (CSE:PXE) (FSE:WH4) is pleased to announce the addition of Adam Ivers, CEO of Rumble Gaming, to its Advisory Board.
  • Mr. Ivers brings extensive experience, connections, and marketing expertise within the media and gaming industries.
  • Expressing his enthusiasm about joining P2Earn, Mr. Ivers stated, "I see a very clear path for Rumble Gaming and P2Earn to collaborate and I'm thrilled to contribute to their growth story.
  • We look forward to benefitting from Mr. Ivers' experience, knowledge, and connections in successfully marketing to both game players and builders.

Inozyme Pharma Reports First Quarter 2023 Financial Results and Provides Business Highlights

Retrieved on: 
Tuesday, May 9, 2023
PIP, Therapy, Doctor of Philosophy, ECTS, European Medicines Agency, Clinical trial, G&A, European Congress of Mathematics, EMA, Patient, Investment, Administration, PXE, Research and development, ECE, R, Conference, Caregiver, Safety, Pharmaceutical industry, Nursing, Generic drug

BOSTON, May 09, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today reported financial results for the first quarter ended March 31, 2023, and provided business highlights.

Key Points: 
  • BOSTON, May 09, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today reported financial results for the first quarter ended March 31, 2023, and provided business highlights.
  • The Company announced the first self-administration of INZ-701 in the open-label Phase 2 portion of the ongoing clinical trial.
  • General and Administrative (G&A) Expenses – G&A expenses were $6.5 million for the quarter ended March 31, 2023, compared to $5.0 million for the prior-year period.
  • Net Loss – Net loss was $17.4 million, or $0.40 loss per share, for the quarter ended March 31, 2023, compared to $16.9 million, or $0.71 loss per share, for the prior-year period.